Skip to main content
SMFM 2026 Pregnancy Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared outside of the session
Faculty have requested this content not be shared outside of the session
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Recording available 2/16-5/2
Recording available 2/16-5/2
AIUM Credit
AIUM Credit
Foundation Awardee
Foundation Awardee
Poster Icons
Abstract Award
Abstract Award
Foundation Awardee
Foundation Awardee

Poster Session 1

Category: Genetics

Poster Session 1

(308) Adverse pregnancy outcomes associated with cystic fibrosis carriers

Wednesday, February 11, 2026
10:30 AM - 12:00 PM  
Objective:

Since 2001, the American College of Obstetrics and Gynecology (ACOG) has recommended cystic fibrosis (CF) screening in pregnancy for individuals at elevated risk. In 2011 ACOG updated their recommendation to universal screening in pregnant individuals. Despite increasing numbers of pregnant individuals learning they are carriers for CF, data regarding the impact of this status on pregnancy outcomes remain limited. This study aimed to investigate the risk of adverse perinatal outcomes in CF carriers compared to those without CF.

Study Design:

This is a retrospective cohort study using linked vital statistics and hospital discharge data for births in California (2008-2020). We included pregnant individuals with singleton gestation who delivered between 23 and 42 weeks. We compared demographic characteristics and outcomes between pregnant individuals who are CF carriers to those without a CF mutation. ICD-9 and ICD-10 codes were used to identify CF carriers (V83.81/Z14.1). Chi-square tests and multivariable Poisson regression models were used to assess risk of outcomes.

Results:
A total of 5,395,388 births were included, with 11,851 (0.22%) identified as CF carriers. CF carriers were more likely be non-Hispanic White (60.0% vs 26.5%,), to have private insurance (75.4% vs 48.4%,), and be nulliparous (46.4% vs 39.4%,) than those without. After adjusting for confounders, CF carriers were more likely to develop hypertensive disease of pregnancy (aRR = 1.25, 95% CI 1.19-1.31), severe maternal morbidity (aRR = 1.30, 95% CI 1.12-1.51), non-transfusion severe maternal morbidity (aRR 1.30, 95% CI 1.04-1.63), PPROM (aRR = 1.29, 95% CI 1.15-1.44), and neonatal hypoglycemia (aRR = 1.39, 95% CI 1.25-1.54).

Conclusion:

We found that CF carriers are at increased risk of adverse perinatal outcomes. These findings can be used for patient counseling and delivery planning. Future studies should further investigate these findings and strategies to mitigate these risks.